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Background: Different long term healing patterns are frequently observed with Optical
Coherence Tomography (OCT) following stent implantation. Although some of these
findings seem to suggest abnormal healing, the clinical implications of these findings are
still unknown.
Methods: A total of 99 patients in whom a stent was implanted (total of 125 stents, 32
bare metal stents (BMS), 30 paclitaxel-eluting stents (PES), and 63 sirolimus-eluting
stents (SES)) were followed with angiography and OCT beyond 3 years (aver-
age4.92.1 years). Strut by strut analysis was performed in 3,053 cross-sectional
images yielding to a total of 30,302 analyzable images. Peri-strut Low Intensity (PLI)
images were defined as the presence of homogenous low intensity area around a stent strut
without significant signal attenuation behind the area. The severity of PLI was assessed by
quantifying the number and degree of PLI features in all analyzable imaging frames.
Results: PLI presence was found in 19.4% of BMS, 12.6% of PES, and 6.0% of SES
struts (p0.001). The mean neointimal thickness on struts with PLI was significantly
higher than that without PLI regardless of the stent type (BMS 0.620.30 versus
0.290.18 mm; PES0.470.27 versus 0.190.18 mm; SES0.560.31 versus
0.140.15 mm; p0.001). The severity of PLI correlated with the neointimal area and
also with angiographical late loss in all stent types (r0.407 to 0.846, p0.05). The
severity of PLI correlated with angiographical binary restenosis even after adjustment
with neointimal area in all stent types (odds ratio9.785 to 34.72, p0.05).
Conclusions: The presence of PLI in neointima appears to correlate with the severity of
neointimal proliferation in the late phases of stent healing. The clinical implications of
these findings need further investigation.
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Background: Optical frequency domain imaging (OFDI) can delineate calcified plaque
whereas intravascular ultrasound has limited visualization of depth of calcification. The
aim of this study was to evaluate the ability of OFDI to quantify and qualify calcification
using ex-vivo imaging with autopsy cases.
Methods: Eighty nine coronary segments from 11 cadavers received ex-vivo imaging by
OFDI. Thirty four matched segments had calcified plaques where the comparison between
OFDI images and histology had performed. The thickness of calcification was measured both
in OFDI and histology. Additionally, the existence of lipid components (lipid pool or necrotic
core) behind or adjacent to calcification were recorded by histological examinations.
Results: There was a good correlation in the thickness of calcification between OFDI and
histology (R-square0.61, p0.0001), however, this was not true when the lipid
components exist behind or adjacent to calcification (R¬-square0.083953, p0.4495).
The calcification with clear border in outer layer had significantly less lipid components
as compared to those with attenuation (35% vs 88%, p0.0001).
Conclusions: OFDI has a potential ability to detect and characterize coronary arterial
calcification, however the extent of calcification could be underestimated when the lipid
components exists adjacent to calcification.
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Background: This study aimed to compare the neointimal coverage (NIC), thrombus,
color of plaque underneath the stent at 9-month after implantation of sirolimus-eluting
stent (SES) either with durable or with biodegradable polymer (BDPM).
Methods: A total of 175 patients were assigned as Cypher (n81) and Excel (n94, with
BDPM) stent at 9-month after indexed procedure. NIC was classified from Grade 0-3.
Color of plaque was divided into white, light-yellow, yellow and dark yellow. Thrombus
was diagnosed as material with cotton-like or ragged appearance. Incomplete NIC (Grade
0/1) circled by a blush was termed by “inflaming”.
Results: More patients in Excel group had unstable angina, previous myocardial
infarction, less silent ischemia, and decreased left ventricular eject fraction compared to
Cypher group. The minimal- and maximal-NIC grades in the Cypher group were
0.670.58 and 2.290.46, respectively, compared to 1.450.67 (p0.001) and
2.640.49 (p0.023) in the Excel group. The percentage of yellow plaque, thrombus,
“inflaming” and NIC grade of 0 in the Excel and Cypher groups, respectively, were as
follow: 8.0% vs. 26.8% (p0.031), 9.8% vs. 32.9% (p0.024), 8.0% vs. 38.1%
(p0.017) and 38.1% vs. 0% (p0.001). Of the stents with “inflaming”, 63.6% had
thrombus compared to 20.1% of the non-inflaming stents (p0.001). Overlapping
segments had the lowest NIC grades and more “inflaming” demonstrating a significant
difference between two groups. NIC grade was positively correlated with thrombus.
Conclusions: SES with BDPM has improved NIC resulting in less yellow plaque,
thrombus and “inflaming”. Overlapping segments had the lowest NIC grade and more
“inflaming”.
Table 4. Angioscopic findings at 9 months
Cypher (N97) Excel (N112) p
No. stented vessels (n) 1.34 0.21 1.34 0.22 1.000
Minor NIC (grade 0-3) 0.67 0.58 1.45 0.67 0.001
Grade 0, % (n) 38.1 (37) 0 (0) 0.001
Grade 1, % (n) 58.8 (57) 41.1 (46) 0.243
Grade 2-3, % (n) 3.1 (3) 58.9 (66) 0.001
Maximal NIC (grade 0-3) 2.29 0.46 2.64 0.49 0.023
Yellow plaque, % (n) 26.8 (26) 8.0 (9) 0.031
Thrombus, % (n) 32.9 (32) 9.8 (11) 0.024
Inflaming, % (n) 38.1 (37) 8.0 (9) 0.017
Stent overlapped, % (n) 11.3 (11) 10.7 (12) 0.733
Minor NIC (grade 0-1) 0.36 0.30 1.08 0.79 0.018
Maximal NIC (grade 2-3) 2.09 0.30 2.17 0.58 0.701
Yellow plaque, % (n) 45.5 (5) 50.0 (6) 0.718
Thrombus, % (n) 72.7 (8) 75.0 (9) 0.531
Inflaming, % (n) 50.0 (4) 22.2 (2) 0.001
DAPT, dual antiplatelet therapy; NIC, neointim coverage; ST, stent thrombosis;
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Background: It has been demonstrated that after the deployment of a bioresorbable
scaffold (BRS) a thick fibromuscular tissue develops that covers the vessel wall. However
the effect of the composition of the plaque on neointimal proliferation remains unclear.
Methods: We analyzed data from 20 patients who were treated with a BRS and had
optical coherence tomography (OCT) at baseline, at 6 months and at 2 years follow-up.
Two experts identified the circumferential location of the lipid and calcific tissue in the
OCT data and measured the thickness of the overlaying tissue. This information was used
to construct spread out vessel plots that allowed comprehensive visualization of the the
spatial location of the plaque components (Figure: the red color corresponds to lipid the
white to calcific and the green to fibrous tissue). The extent of each plaque component was
expressed as percentage of the total plaque.
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Results: The extent of the calcific tissue did not change at follow-up (4.084.31% at
baseline vs. 3.414.05% at 6 months and 4.054.05% at 2 years, P0.394) while the
extent of the lipid component decreased (17.578.24% at baseline vs. 8.086.71% at 6
months and 2.693.62% at 2 years, P0.001). The thickness of the overlaying tissue
increased at follow-up in both the lipid cores (by 104m at 6 months and by 157m at
2 years comparing to baseline; P0.001) and calcific spots (by 76m at 6 months and by
105m at 2 years comparing to baseline, P0.001).
Conclusions: It appears that in BRSs the plaque type does not affect neointimal
formation which can cover both lipid and calcific tissues.
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Background: Previous studies have recommended positioning the stent edge at a site of
plaque burden 50%. The aim of this study was to investigate whether targeting less
plaque burden beyond this threshold can further contribute to better lumen preservation at
the stent edge after DES implantation.
Methods: Data were derived from the J-DESsERT trial, a prospective, randomized,
multi-center study, comparing sirolimus- and paclitaxel-eluting stents in de novo native
coronary lesions. IVUS was performed at pre-, post-intervention, and 8-month follow-up.
Volume index (VI: volume/length, mm3/mm) was measured for vessel, lumen, plaque
within the 5-mm reference segments adjacent to the stent edges. % plaque volume (%PV)
was calculated as plaque volume divided by vessel volume. Edge stenosis at follow-up
was defined as the minimum lumen area (MLA) 4 mm2 at the reference segment.
Results: %PV 50% at pre-intervention was achieved in 106 reference segments (61
distal: 45 proximal). Lumen, vessel, and plaque VI, and MLA at pre-intervention were
significantly smaller in the edge stenosis group than the no edge stenosis. However, %PV
was similar between the 2 groups (37.78.1 vs 37.18.2%, respectively, p0.72).
Univariate logistic regression analyses showed no contribution of %PV at pre-intervention
to MLA at follow-up (OR: 0.99, p0.72). These results were consistent, when the distal
and proximal segments were separately analyzed.
Edge
Stenosis
(n33)
No Edge
Stenosis
(n73) p
Pre-intervention
Lumen VI (mm3/mm) 4.8 2.0 8.6 3.1 0.001
Vessel VI (mm3/mm) 7.6 3.4 14.0 5.5 0.001
Plaque VI (mm3/mm) 3.0 1.6 5.4 2.7 0.001
Minimum lumen area (mm2) 4.0 1.7 7.5 2.8 0.001
% Plaque volume (%) 37.7 8.1 37.1 8.2 0.719
Follow-up
Lumen VI (mm3/mm) 4.1 0.9 8.3 2.8 0.001
Vessel VI (mm3/mm) 8.1 2.7 14.5 5.3 0.001
Plaque VI (mm3/mm) 4.0 2.1 6.2 3.2 0.001
Minimum lumen area (mm2) 3.1 0.7 6.9 2.3 0.001
% Plaque volume (%) 47.0 10.1 41.4 9.2 0.006
Conclusions: In lesions with the stent edge positioned at a site of plaque burden50%,
%PV at pre-intervention did not predict stent edge stenosis at follow-up. This result
suggests that aggressive lesion coverage strategy targeting further less plaque burden
beyond 50% as the stent landing zone may not offer additional benefit on lumen
preservation at the stent edge.
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Background: Recent trials using intravascular ultrasound (IVUS) have shown that statin
produces regression and stabilization of coronary artery plaques. The TRUTH study was
a prospective, open-labeled, randomized and multicenter trial to evaluate the effects of
8-month treatment with pitavastatin versus pravastatin on coronary artery plaque com-
position using virtual histology (VH)-IVUS. This study demonstrated that both statins
altered coronary artery plaque composition by significantly decreasing the fibro-fatty
component and increasing the dense-calcium component. However, there are no reports
whether plaque regression or changes in plaque composition using statin could extend
because no study has serially monitored coronary artery plaques for a long-term.
Methods: Among 164 patients who participated in the TRUTH trial, additional IVUS
examination was performed in 39 patients (mean follow-up period 4810 months). IVUS
images qualifying for evaluation at baseline, at 8-month, and at 48-month were obtained
in 30 patients.
Results: Mean age was 679 years and 27 patients (90%) were men. Twenty patients
(67%) were treated with allocated statins without change in the dose at the TRUTH study,
and the dose or type of statin was changed in another 12 patients (40%). Significant
decrease in LDL-C (from 130 to 80 mg/dl, p0.0001) and hs-CRP (from 3690 to 487
ng/ml, p0.001) were observed at 48-month follow-up. HDL-C levels also increased
significantly at 48-month (from 45 to 50 mg/dl, p0.05). Significant decrease in external
elastic membrane volume (-1.1% at 8-month and -5.9% at 48-month) and plaque volume
(-0.5% at 8-month and -3.9% at 48-month) have extended. Furthermore, significant
increase in dense-calcium component (from 0.56 to 0.65 mm3/mm at 8-month and 0.77
mm3/mm at 48-month) and decrease in fibro-fatty component (from 1.09 to 0.94
mm3/mm at 8-month and 0.86 mm3/mm at 48-month) have also extended.
Conclusions: Coronary artery plaque regression and change in plaque composition
associated with statin therapy extend for a long-term. These changes in coronary
atherosclerosis may lead to beneficial effects of statins on long-term clinical outcomes.
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